What is Commense?
Commense is a biotechnology company focused on developing novel therapeutics derived from a deep understanding of human-microbe interactions and their impact on health. The company's research is particularly informed by the growing body of evidence linking C-section deliveries to increased risks of allergies, immune disorders, asthma, and obesity. By seeding newborns with microbes from the mother's birth canal, mimicking natural birth, Commense aims to enhance natural microbial colonization and address these health concerns. Their pipeline of therapeutics is built upon this foundational scientific insight.
How much funding has Commense raised?
Commense has raised a total of $40M across 1 funding round:
Series B
$40M
Series B (2017): $40M with participation from Fidelity Management & Research Company, Rock Springs Capital, OrbiMed, and Nest Bio
Key Investors in Commense
Fidelity Management & Research Company
Fidelity Investments is a leading financial services firm providing a wide array of investment and wealth management solutions. Their participation suggests a belief in Commense's long-term financial viability and market potential.
OrbiMed
OrbiMed is a specialized investment firm with deep expertise in the healthcare sector, managing capital across biopharmaceuticals, medical devices, and digital health. Their involvement indicates a strong strategic alignment with Commense's therapeutic focus.
Nest Bio
Nest.bio is a venture firm dedicated to transforming breakthrough life sciences and healthcare technologies into revolutionary companies. Their investment in Commense highlights the company's innovative approach to microbiome therapeutics.
What's next for Commense?
The substantial enterprise-level funding, including a recent major strategic investment, positions Commense for significant advancement in its therapeutic development pipeline. This capital infusion is likely to accelerate research, clinical trials, and the scaling of its innovative microbiome-based treatments. The company's focus on a critical area of infant health, supported by prominent investors in the life sciences sector, suggests a strategic push towards establishing a strong market presence and potentially addressing unmet medical needs in immune and metabolic disorders.
See full Commense company page
